(Q35798168)

10 August 2017

1 reference

title

Natural killer T cells as targets for immunotherapy of autoimmune diseases (English)

1 reference

10 August 2017

1 reference

1

Luc Van Kaer

1 reference

10 August 2017

1 June 2004

1 reference

Immunology & Cell Biology

10 August 2017

1 reference

10 August 2017

82

1 reference

10 August 2017

315-322

1 reference

10 August 2017

3

1 reference

Mouse CD1-specific NK1 T cells: development, specificity, and function

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

NKT cells: facts, functions and fallacies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

CD1d and natural T cells: how their properties jump-start the immune system

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The regulatory role of Valpha14 NKT cells in innate and acquired immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The unconventional lifestyle of NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Regulation of immune responses by CD1d-restricted natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

NKT cells: what's in a name?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Autoreactivity by design: innate B and T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Role of CD1d-restricted NKT cells in microbial immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

NKT cells - conductors of tumor immunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Natural killer T cells as targets for therapeutic intervention in autoimmune diseases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Janus-like role of regulatory iNKT cells in autoimmune disease and tumour immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Natural killer T cells: natural or unnatural regulators of autoimmunity?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Essential role of NKT cells producing IL-4 and IL-13 in the development of allergen-induced airway hyperreactivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Natural killer T cells contribute to airway eosinophilic inflammation induced by ragweed through enhanced IL-4 and eotaxin production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Exacerbated Th2-mediated airway inflammation and hyperresponsiveness in autoimmune diabetes-prone NOD mice: a critical role for CD1d-dependent NKT cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Cutaneous immunization rapidly activates liver invariant Valpha14 NKT cells stimulating B-1 B cells to initiate T cell recruitment for elicitation of contact sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

CD4(+) Valpha14 natural killer T cells are essential for acceptance of rat islet xenografts in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Requirement for natural killer T (NKT) cells in the induction of allograft tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

CD1d and invariant NKT cells at the human maternal-fetal interface.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Mechanism of CD1d-restricted natural killer T cell activation during microbial infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Cross-presentation of disialoganglioside GD3 to natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Murine CD1d-restricted T cell recognition of cellular lipids

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

CD1d-restricted and TCR-mediated activation of valpha14 NKT cells by glycosylceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Fas/Fas ligand interactions promote activation-induced cell death of NK T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The response of natural killer T cells to glycolipid antigens is characterized by surface receptor down-modulation and expansion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Down-regulation of the invariant Valpha14 antigen receptor in NKT cells upon activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Mouse V alpha 14i natural killer T cells are resistant to cytokine polarization in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Selective bystander proliferation of memory CD4+ and CD8+ T cells upon NK T or T cell activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Prolonged IFN-gamma-producing NKT response induced with alpha-galactosylceramide-loaded DCs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Immunization with alpha-galactosylceramide polarizes CD1-reactive NK T cells towards Th2 cytokine synthesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Therapeutic activation of Vα24+Vβ11+ NKT cells in human subjects results in highly coordinated secondary activation of acquired and innate immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

A synthetic glycolipid prevents autoimmune encephalomyelitis by inducing TH2 bias of natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Superior protection against malaria and melanoma metastases by a C-glycoside analogue of the natural killer T cell ligand alpha-Galactosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Dissociation of NKT stimulation, cytokine induction, and NK activation in vivo by the use of distinct TCR-binding ceramides

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Immunotherapy with ligands of natural killer T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

NKT cells: potential targets for autoimmune disease therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Natural killer T (NKT) cells and their role in antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The NOD mouse model of type 1 diabetes: as good as it gets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The nonobese diabetic mouse as a model of autoimmune diabetes: immune dysregulation gets the NOD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

An update on cytokines in the pathogenesis of insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Overexpression of natural killer T cells protects Valpha14- Jalpha281 transgenic nonobese diabetic mice against diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

alpha/beta-T cell receptor (TCR)+CD4-CD8- (NKT) thymocytes prevent insulin-dependent diabetes mellitus in nonobese diabetic (NOD)/Lt mice by the influence of interleukin (IL)-4 and/or IL-10.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Germ line deletion of the CD1 locus exacerbates diabetes in the NOD mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

CD1-restricted NK T cells protect nonobese diabetic mice from developing diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Activation of CD1d-restricted T cells protects NOD mice from developing diabetes by regulating dendritic cell subsets

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Interleukin-4 but not interleukin-10 protects against spontaneous and recurrent type 1 diabetes by activated CD1d-restricted invariant natural killer T-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Assessment of animal models for MS and demyelinating disease in the design of rational therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Natural killer T cell activation protects mice against experimental autoimmune encephalomyelitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Activation of natural killer T cells potentiates or prevents experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Defective IgE production by SJL mice is linked to the absence of CD4+, NK1.1+ T cells that promptly produce interleukin 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Suppression of collagen-induced arthritis by natural killer T cell activation with OCH, a sphingosine-truncated analog of alpha-galactosylceramide

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Activation of natural killer T cells in NZB/W mice induces Th1-type immune responses exacerbating lupus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

The immunology of mucosal models of inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Autoimmune and inflammatory mechanisms in atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

CD1d-dependent activation of NKT cells aggravates atherosclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

Involvement of decidual Valpha14 NKT cells in abortion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0818-9641.2004.01252.X

10.1111/J.0818-9641.2004.01252.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15186263